<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719612</url>
  </required_header>
  <id_info>
    <org_study_id>DEF-315</org_study_id>
    <nct_id>NCT03719612</nct_id>
  </id_info>
  <brief_title>DEF-315 Better Accuracy in EF Assessment With DEFINITY</brief_title>
  <acronym>BENEFIT2</acronym>
  <official_title>A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY®-Enhanced 2D-Echo and Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lantheus Medical Imaging</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, prospective, open-label, multicenter study to evaluate LVEF measurement
      accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography
      as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth
      standard.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in LVEF measurement accuracy</measure>
    <time_frame>41 days</time_frame>
    <description>Demonstrate improvements in left ventricular ejection fraction measurement accuracy from unenhanced 2D echo imaging to imaging with DEFINITY® contrast-enhanced 2D echo using cardiac magnetic resonance imaging as the truth standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in LVEF measurement accuracy in subjects with suboptimal echocardiograms</measure>
    <time_frame>41 days</time_frame>
    <description>Demonstrate improvement in accuracy in left ventricular ejection franction measurement assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in inter-reader variability in assessing LVEF</measure>
    <time_frame>41 days</time_frame>
    <description>Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction measurement using DEFINITY® contrast-enhanced versus unenhanced echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in inter-reader variability in assessing end-diastolic/systolic volumes</measure>
    <time_frame>41 days</time_frame>
    <description>Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volume measurements using DEFINITY® contrast-enhanced versus unenhanced echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in inter-reader variability in assessing LVEF in subjects with suboptimal echocardiograms</measure>
    <time_frame>41 days</time_frame>
    <description>Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction measurements using DEFINITY® contrast-enhanced versus unenhanced echocardiography in subjects with suboptimal echocardiograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in inter-reader variability in assessing end-diastolic/systolic volumes in subjects with suboptimal echocardiograms</measure>
    <time_frame>41 days</time_frame>
    <description>Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volume measurements using DEFINITY® contrast-enhanced versus unenhanced echocardiography in subjects with suboptimal echocardiograms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>DEFINITY®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEFINITY®</intervention_name>
    <description>All subjects will receive a single dose of DEFINITY®</description>
    <arm_group_label>DEFINITY®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>All subjects will undergo an unenhanced and DEFINITY®-enhanced ultrasound.</description>
    <arm_group_label>DEFINITY®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ≥ 18 years of age in sinus rhythm

          2. Able to communicate effectively with trial personnel

          3. LVEF measurements obtained via 2D Echo with or without contrast or other methods (e.g.
             CMR, MUGA scan) obtained within 6 months prior to enrollment (Day 0)

          4. Has provided signed informed consent after receiving a verbal and written explanation
             of this clinical trial

        Exclusion Criteria:

          1. Female subjects who are pregnant or lactating. All women of child bearing potential
             [WOCBP] must have a negative urine pregnancy test at screening regardless of
             contraceptive use history.

          2. Women of child-bearing potential are excluded unless they:

               1. are post-menopausal defined as amenorrhea ≥ 12 consecutive months, OR

               2. have undergone successful surgical sterilization (hysterectomy, bilateral tubal
                  ligation or bilateral oophorectomy), OR

               3. have been using an adequate and medically approved method of contraception to
                  avoid pregnancy for at least 1 month prior to DEFINITY® dose administration and
                  be willing to continue using the same method for the duration of the study.

          3. Current illness or pathology that would prevent undergoing investigational product
             administration due to a significant safety risk to the patient.

          4. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or
             diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic
             blood pressure ≤ 90 mmHg).

          5. Unstable cardiovascular status defined as:

               1. myocardial infarction or unstable angina pectoris within 6 months prior to
                  enrollment/DEFINITY® dose administration day

               2. transient ischemic attack or stroke within 3 months prior to DEFINITY® dose
                  administration

               3. symptomatic valvular heart disease or moderate to severe stenotic valvular heart
                  disease

               4. clinically significant congenital heart defects

               5. current uncontrolled cardiac arrhythmias causing symptoms or hemodynamic
                  compromise

               6. acute pulmonary embolus or pulmonary infarction

               7. acute myocarditis or pericarditis

               8. acute aortic dissection

               9. atrial fibrillation

          6. any major surgery within 4 weeks prior to screening

          7. known contraindications to undergoing CMR (e.g. implanted pacemakers, cardioverter,
             defibrillators) or claustrophobia

          8. participation in any investigational drug, device, or placebo study within 30 days
             prior to screening

          9. known hypersensitivity to perflutren, or any of the excipients in DEFINITY®

         10. prisoners or those who are subject to compulsory detention or involuntary
             incarceration for treatment of either a psychiatric or physical illness (e.g.,
             infectious disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfieri Cardiology</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Group</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Unit Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott White Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left Ventricular Ejection Fraction</keyword>
  <keyword>DEFINITY®</keyword>
  <keyword>Enhanced Echocardiogram</keyword>
  <keyword>Cardiac Magnetic Resonance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

